Helicobacter pylori (H. pylori) is a gram-negative, spiral-shaped bacterium that infects the stomach lining, causing chronic gastritis, peptic ulcers, and increasing the risk of gastric lymphoma and carcinoma.
It is one of the most common chronic bacterial infections worldwide, affecting up to 50% of the global population, with higher prevalence in developing countries.
H. pylori is typically acquired in early childhood and can persist without treatment. The bacterium's ability to survive in the acidic environment of the stomach is attributed to various virulence factors.
Its high mutation and recombination rates lead to extensive strain diversity.
While many infected individuals remain asymptomatic, H. pylori can cause symptoms such as abdominal pain, nausea, vomiting, and dyspepsia when gastritis or peptic ulcer disease develops.
Diagnosis involves non-invasive methods like urea breath tests and stool antigen tests, and invasive methods such as endoscopic biopsy. Treatment generally includes a combination of proton pump inhibitors and antibiotics.
The outer inflammatory protein A (OipA), encoded by the oipA gene, is a major virulence factor of Helicobacter pylori that contributes to the pathogenesis of gastric diseases.
OipA is a protein localized in the bacterial outer membrane that plays a role in the attachment of H. pylori to gastric epithelial cells, which is a crucial step in establishing persistent bacterial colonization and pathogenesis.
OipA's production is controlled by a mechanism that allows variable levels of its production to facilitate bacterial colonization and pathogenesis.
Helicobacter pylori (H. pylori) is a gram-negative, spiral-shaped bacterium that infects the stomach lining and is a common cause of chronic gastritis, peptic ulcers, gastric lymphoma, and gastric carcinoma.
It affects up to 50% of the global population, with higher prevalence in developing countries. It is one of the most common chronic bacterial infections worldwide.
H. pylori is typically acquired in early childhood and persists without treatment.
It is able to survive in the harsh acidic environment of the stomach due to its unique features like flagella for motility and urease enzyme production.
Its genome exhibits high mutation and recombination rates, leading to extensive strain diversity. [10., 14.]
While many infected individuals remain asymptomatic, the bacteria can cause symptoms such as abdominal pain, nausea, vomiting, and dyspepsia once gastritis or peptic ulcer disease develops. H. pylori infection causes chronic gastritis in all cases and increases the risk of peptic ulcers by 2-6 fold and gastric cancer by 2-6 fold compared to uninfected individuals. [5., 10.]
Transmission occurs through fecal-oral, oral-oral, and gastric-oral routes, with lower socioeconomic status being a significant risk factor.
Diagnosis involves both non-invasive methods like urea breath tests and stool antigen tests, and invasive methods such as endoscopic biopsy.
Treatment often includes a combination of proton pump inhibitors and antibiotics. Antibiotic combination therapies like clarithromycin triple therapy or bismuth quadruple therapy may be used. [5.]
Early identification and treatment of H. pylori infections are crucial to prevent serious gastrointestinal diseases and potential malignancies. Collaboration among healthcare professionals is essential for effective management and improved patient outcomes.
H. pylori virulence factors refer to the various bacterial components and mechanisms that enable the pathogen Helicobacter pylori to successfully colonize the human stomach, evade the host's immune defenses, and cause associated diseases and complications.
OipA, an outer membrane protein of Helicobacter pylori, functions as an adhesin, facilitating the bacterium's attachment to gastric epithelial cells.
Its activity is regulated by a mechanism called slipped-strand mispairing, which involves changes in the number of CT dinucleotide repeats in the gene's 5' region, switching between functional ("on") and non-functional ("off") states.
Initially identified as a protein inducing a proinflammatory response, OipA mutants have been shown to reduce IL-8 induction from gastric epithelial cells, suggesting its role in inflammation.
OipA also influences actin dynamics and various signaling pathways that interact with cag PAI (CagA)-related pathways.
OipA is an outer membrane protein in Helicobacter pylori that plays a crucial role in the bacterium's adhesion to gastric epithelial cells and in mediating the translocation of the oncoprotein CagA, a major virulence factor.
OipA's role in IL-8 secretion and inflammation has been controversial, with some studies showing it as a proinflammatory protein that induces IL-8, while others have disputed this finding. [9.]
However, recent research has shown that OipA is necessary for IL-8 production in the presence of a functional cag pathogenicity island (PAI), but it is not sufficient on its own to induce IL-8 secretion. [9.]
Additionally, OipA is critical for the effective translocation of CagA into host cells via the type IV secretion system (T4SS) encoded by the cag PAI.
Studies have demonstrated that phase on OipA increases adherence to human gastric adenocarcinoma (AGS) cells and correlates with higher oipA mRNA levels in these adherent cells compared to non-adherent ones. This suggests that OipA's expression is upregulated upon contact with host cells, facilitating H. pylori's colonization and pathogenicity.
The close association of OipA with cag PAI-positive strains underscores its role in enhancing the bacterium's virulence, making it a potential target for therapeutic interventions against H. pylori-related diseases.
Interestingly, most East Asian strains are classified as oipA "on," with specific CT-repeat sequences preventing easy switching to "off" status.
Recent whole-genome sequencing revealed two oipA genes in East Asian strains, but not in Western strains, suggesting a novel DNA duplication mechanism associated with inversion. [12.]
Laboratory testing for H. pylori virulence factors typically involves a stool sample, which is tested via polymerase chain reaction (PCR) for H. pylori virulence factors.
The stool sample may be collected at home. While special preparation is not typically required for this assessment, other test components may require special preparation such as avoidance of certain foods, supplements or medications.
Click here to discover a laboratory test that assesses for H. pylori and virulence factors.
H. pylori infections can cause serious conditions including peptic ulcer disease and gastric cancer, and the presence of virulence factors such as the oipA virulence factor may increase the risk of developing peptic ulcer disease, gastritis, and/or gastric cancer.
Optimal levels of H. pylori virulence factor oipA are undetectable.
A positive test result indicates the presence of H. pylori and the virulence factor oipA, which requires prompt treatment.
Typical first-line eradication therapies may include medications such as clarithromycin, bismuth, amoxicillin, metronidazole, or tetracycline in combination, along with a PPI.
The presence of oipA-positive strains may indicate the need for more intensive therapies, including anti-inflammatory compounds. [2., 13.]
With the increase in antibiotic resistance demonstrated by H. pylori, especially in the setting of virulence factor-positive strains, scientists are exploring alternative methods of treating H. pylori including botanical therapies.
Some botanical compounds that have shown promise in treating H. pylori include: [6.]
In addition to the oipA virulence factor, several other biomarkers have been identified and studied in the context of H. pylori infection and associated gastric diseases.
The cytotoxin-associated gene A (CagA) is a major virulence factor of H. pylori that has been extensively studied for its role in gastric cancer development.
The presence of CagA has been strongly associated with an increased risk of gastric cancer.
In Western countries, infection with BabA-producing strains is associated with an increased risk of peptic ulcer disease.
A recent study indicated that BabA-positive H. pylori strains have a higher adherence to epithelial cells and are often found in pediatric ulcerogenic H. pylori strains.
BabA-positive H. pylori strains can be classified as "specialists," which bind only blood group O-specific glycans, or "generalists," which bind glycans of blood groups O, A, and B.
The ability of these strains to bind specifically to blood group O glycans explains why individuals with blood group O are at a higher risk for developing duodenal ulcers.
The vacuolating cytotoxin A (VacA) is another important virulence factor of H. pylori that contributes to the pathogenesis of peptic ulcers. VacA induces the formation of vacuoles in gastric epithelial cells, leading to cellular damage and disruption of the gastric mucosal barrier.
The presence of the vacA gene and its specific allelic variations have been linked to an increased risk of peptic ulcer disease and gastric inflammation.
In addition to bacterial virulence factors, serological biomarkers such as anti-H. pylori antibodies can also be used for the diagnosis and monitoring of H. pylori infection.
These antibodies are produced by the host's immune system in response to the bacterial antigens and can be detected in serum or plasma samples.
Click here to compare testing options and order tests for H. pylori.
Hey Practitioners! Want to learn from New York Times best-selling author Dr. Casey Means? In this upcoming free live class for practitioners, Dr. Means will teach us about the clinical importance of understanding metabolic health in every patient, how to test for it, and key dietary and lifestyle changes that can start to improve it. Sign up here!
[1.] Ansari S, Yamaoka Y. Helicobacter pylori Virulence Factors Exploiting Gastric Colonization and its Pathogenicity. Toxins (Basel). 2019 Nov 19;11(11):677. doi: 10.3390/toxins11110677. PMID: 31752394; PMCID: PMC6891454.
[2.] Caner V, Yilmaz M, Yonetci N, Zencir S, Karagenc N, Kaleli I, Bagci H. H pylori iceA alleles are disease-specific virulence factors. World J Gastroenterol. 2007 May 14;13(18):2581-5. doi: 10.3748/wjg.v13.i18.2581. PMID: 17552005; PMCID: PMC4146818.
[3.] Chakrani, Z., Robinson, K. & Taye, B. Association Between ABO Blood Groups and Helicobacter pylori Infection: A Meta-Analysis. Sci Rep 8, 17604 (2018). https://doi.org/10.1038/s41598-018-36006-x
[4.] Chang, WL., Yeh, YC. & Sheu, BS. The impacts of H. pylori virulence factors on the development of gastroduodenal diseases. J Biomed Sci 25, 68 (2018). https://doi.org/10.1186/s12929-018-0466-9
[5.] Connor B. Helicobacter Pylori | CDC Yellow Book 2024. wwwnc.cdc.gov. Published 2024. https://wwwnc.cdc.gov/travel/yellowbook/2024/infections-diseases/helicobacter-pylori
[6.] Deng R, Chen X, Zhao S, Zhang Q, Shi Y. The effects and mechanisms of natural products on Helicobacter pylori eradication. Frontiers in cellular and infection microbiology. 2024;14. doi:https://doi.org/10.3389/fcimb.2024.1360852
[7.] Donelli LC Gianfranco. Virulence Factors of Helicobacter pylori. Microbial Ecology in Health and Disease. 2000;12(2):259-262. doi:https://doi.org/10.1080/089106000750060512
[8.] Doohan D, Rezkitha YAA, Waskito LA, Yamaoka Y, Miftahussurur M. Helicobacter pylori BabA–SabA Key Roles in the Adherence Phase: The Synergic Mechanism for Successful Colonization and Disease Development. Toxins. 2021;13(7):485. doi:https://doi.org/10.3390/toxins13070485
[9.] Horridge DN, Begley AA, Kim J, Aravindan N, Fan K, Forsyth MH. Outer inflammatory protein a (OipA) of Helicobacter pylori is regulated by host cell contact and mediates CagA translocation and interleukin-8 response only in the presence of a functional cag pathogenicity island type IV secretion system. Pathogens and Disease. 2017;75(8). doi:https://doi.org/10.1093/femspd/ftx113
[10.] Malfertheiner, P., Camargo, M.C., El-Omar, E. et al. Helicobacter pylori infection. Nat Rev Dis Primers 9, 19 (2023). https://doi.org/10.1038/s41572-023-00431-8
[11.] Parikh NS, Ahlawat R. Helicobacter Pylori. [Updated 2023 Aug 8]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK534233/
[12.] Shiota S, Suzuki R, Yamaoka Y. The significance of virulence factors in Helicobacter pylori. J Dig Dis. 2013 Jul;14(7):341-9. doi: 10.1111/1751-2980.12054. PMID: 23452293; PMCID: PMC3721066.
[13.] Shiota S, Watada M, Matsunari O, Iwatani S, Suzuki R, Yamaoka Y. Helicobacter pylori iceA, Clinical Outcomes, and Correlation with cagA: A Meta-Analysis. Katoh M, ed. PLoS ONE. 2012;7(1):e30354. doi:https://doi.org/10.1371/journal.pone.0030354
[14.] Thorell, K., Muñoz-Ramírez, Z.Y., Wang, D. et al. The Helicobacter pylori Genome Project: insights into H. pylori population structure from analysis of a worldwide collection of complete genomes. Nat Commun 14, 8184 (2023). https://doi.org/10.1038/s41467-023-43562-y